A voxel-based morphometry and diffusion tensor imaging analysis of asymptomatic Parkinson's disease-related G2019S LRRK2 mutation carriers

Movement Disorders

Volumn 29, Issue 6, 2014, Pages 823-827

  Thaler, Avner ^a,b   Artzi, Moran ^a,b   Mirelman, Anat ^a   Jacob, Yael ^a   Helmich, Rick C ^c   van Nuenen, Bart F L ^c,d   Gurevich, Tanya ^a,b   Orr Urtreger, Avi ^a,b   Marder, Karen ^e   Bressman, Susan ^f   Bloem, Bastiaan R ^c   Hendler, Talma ^a,b   Giladi, Nir ^a,b   Ben Bashat, Dafna ^a,b   Saunders Pullman, Rachel ^f   Shanker, Vicki Lynn ^f   Groves, Mark ^f   Palmese, Christine ^f   Stanley, Kaili Maloy ^f   Iyer, Akhila ^f   Soto Valencia, Jeannie ^f   Raymond, Deborah ^f   San Luciano, Marta ^f   Deik, Andres ^f   Barrette, Matthew James ^f   Cabbasa, Jose ^f   Severt, Lawrence ^f   Hunt, Ann ^f   Lubarr, Naomi ^f   Sachdev, Rivka ^f   Lewis, Sara ^f   Ozelius, Laurie ^f,g   Alcalay, Roy ^h   Fahn, Stanley ^h   Cote, Lucien ^h   Greene, Paul ^h   Waters, Cheryl ^h   Mazzoni, Pietro ^h   Ford, Blair ^h   Louis, Elan ^h   Levy, Oren ^h   Tang, Ming Xin ^h   Rakitin, Brian ^h   Mejia, Helen ^h   Roos, Ernest ^h   Riley, Martha Orbe ^h   Rosado, Llency ^h   Moskowitz, Carol ^h   Dorovski, Tsvyatko ^h   Clark, Lorraine ^h   Liu, Xinmin ^h   Kisselev, Sergey ^h   Peer, Itsik ^h   Vacic, Vladimir ^h   Balash, Yaacov ^a   Hertzel, Shabtai ^a   Or, Ziv Gan ^a   Shira, Anat Bar ^a   Weiss, Mali Gana ^a   Kobo, Hila ^a   Bregman, Noa ^a   Kestenbaum, Meir ^a   Lehrman, Hedva ^a   Sapir, Einat Even ^a   Levy, Shiran ^a   Yasinovsky, Kira ^a   Shkedy, Anat ^a   Zelis, Maayan ^a   more..

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c RADBOUD UNIVERSITY   (Netherlands)

^d CATHARINA HOSPITAL   (Netherlands)

^e Taub Institute for Research on Alzheimer's Disease and the Aging Brain and the Gertrude H Sergievsky Center   (United States)

^f BETH ISRAEL MEDICAL CENTER   (United States)

^g MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^h Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Diffusion tensor imaging; G2019S; LRRK2; Magnetic resonance imaging; Parkinson's disease; Voxel based morphometry

Indexed keywords

LEUCINE RICH REPEAT KINASE 2; GLYCINE; LRRK2 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE; SERINE;

ADULT; AGE; ARTICLE; BECK DEPRESSION INVENTORY; CONTROLLED STUDY; DIFFUSION TENSOR IMAGING; FEMALE; G2019S GENE; GENE; GENE MUTATION; GRAY MATTER; HEALTH CARE; HUMAN; LRRK2 GENE; MAJOR CLINICAL STUDY; MALE; MONTREAL COGNITIVE ASSESSMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; NUCLEUS ACCUMBENS; PARKINSON DISEASE; PRIORITY JOURNAL; PUTAMEN; SEX DIFFERENCE; SUBSTANTIA NIGRA; THALAMUS; UNIFIED PARKINSON DISEASE RATING SCALE; VOXEL BASED MORPHOMETRY; WHITE MATTER; BRAIN; COGNITION DISORDERS; COMPLICATION; GENETICS; MIDDLE AGED; PATHOLOGY; SEVERITY OF ILLNESS INDEX;

ADULT; BRAIN; COGNITION DISORDERS; DIFFUSION TENSOR IMAGING; FEMALE; GLYCINE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; PROTEIN-SERINE-THREONINE KINASES; SERINE; SEVERITY OF ILLNESS INDEX;

EID: 84899931723     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25827     Document Type: Article

References (33)

1. Hilker R, Schweitzer K, Coburger S, et al. Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity. Arch Neurol 2005;62:378-382.
2. Borghammer P, Kumakura Y, Cumming P. Fluorodopa F 18 positron emission tomography and the progression of Parkinson disease [letter]. Arch Neurol 2005;62:1480; author reply 1480-1481.
3. Stoessl AJ. Positron emission tomography in premotor Parkinson's disease. Parkinsonism Relat Disord 2007;13(suppl 3):S421-S424.
4. Appel-Cresswell S, de la Fuente-Fernandez R, Galley S, McKeown MJ. Imaging of compensatory mechanisms in Parkinson's disease. Curr Opin Neurol 2010;23:407-412.
5. Ben Sassi S, Nabli F, Hentati E, et al. Cognitive dysfunction in Tunisian LRRK2 associated Parkinson's disease. Parkinsonism Relat Disord 2012;18:243-246.
6. Ashburner J, Friston KJ. Voxel-based morphometry-the methods. Neuroimage 2000;11(6 pt 1):805-821.
7. Burton EJ, McKeith IG, Burn DJ, O'Brien JT. Brain atrophy rates in Parkinson's disease with and without dementia using serial magnetic resonance imaging. Mov Disord 2005;20:1571-1576.
8. Nagano-Saito A, Washimi Y, Arahata Y, et al. Cerebral atrophy and its relation to cognitive impairment in Parkinson disease. Neurology 2005;64:224-229.
9. Brockmann K, Groger A, Di Santo A, et al. Clinical and brain imaging characteristics in leucine-rich repeat kinase 2-associated PD and asymptomatic mutation carriers. Mov Disord 2011;26:2335-2342.
10. Basser PJ, Pierpaoli C. Microstructural and physiological features of tissues elucidated by quantitative-diffusion-tensor MRI. J Magn Reson B 1996;111:209-219.
11. Yoshikawa K, Nakata Y, Yamada K, Nakagawa M. Early pathological changes in the parkinsonian brain demonstrated by diffusion tensor MRI. J Neurol Neurosurg Psychiatry 2004;75:481-484.
12. Vaillancourt DE, Spraker MB, Prodoehl J, et al. High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease. Neurology 2009;72:1378-1384.
13. Godau J, Hussl A, Lolekha P, Stoessl AJ, Seppi K. Neuroimaging: current role in detecting pre-motor Parkinson's disease. Mov Disord 2012;27:634-643.
14. Fahn S. Unified Parkinson's Disease Rating Scale. Florham Park, NJ: Macmillan Health Care Information; 1987.
15. Nasreddine ZS, Phillips NA, Bedirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005;53:695-699.
16. Schrag A, Barone P, Brown RG, et al. Depression rating scales in Parkinson's disease: critique and recommendations. Mov Disord 2007;22:1077-1092.
17. Orr-Urtreger A, Shifrin C, Rozovski U, et al. The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease: is there a gender effect? Neurology 2007;69:1595-1602.
18. Smith SM, Jenkinson M, Johansen-Berg H, et al. Tract-based spatial statistics: voxelwise analysis of multi-subject diffusion data. Neuroimage 2006;31:1487-1505.
19. Reetz K, Tadic V, Kasten M, et al. Structural imaging in the presymptomatic stage of genetically determined parkinsonism. Neurobiol Dis 2010;39:402-408.
20. Tessitore A, Esposito F, Vitale C, et al. Default-mode network connectivity in cognitively unimpaired patients with Parkinson disease. Neurology 2012;79:2226-2232.
21. van Nuenen BF, Helmich RC, Ferraye M, et al. Cerebral pathological and compensatory mechanisms in the premotor phase of leucine-rich repeat kinase 2 parkinsonism. Brain 2012;135(pt 12):3687-3698.
22. Thaler A, Mirelman A, Helmich RC, et al. Neural correlates of executive functions in healthy G2019S LRRK2 mutation carriers. Cortex 2013;49:2501-2511.
23. Minati L, Grisoli M, Bruzzone MG. MR spectroscopy, functional MRI, and diffusion-tensor imaging in the aging brain: a conceptual review. J Geriatr Psychiatry Neurol 2007;20:3-21.
24. Gattellaro G, Minati L, Grisoli M, et al. White matter involvement in idiopathic Parkinson disease: a diffusion tensor imaging study. AJNR Am J Neuroradiol 2009;30:1222-1226.
25. Lehericy S, Sharman MA, Dos Santos CL, Paquin R, Gallea C. Magnetic resonance imaging of the substantia nigra in Parkinson's disease. Mov Disord 2012;27:822-830.
26. Du G, Lewis MM, Sen S, et al. Imaging nigral pathology and clinical progression in Parkinson's disease. Mov Disord 2012;27:1636-1643.
27. Boska MD, Hasan KM, Kibuule D, et al. Quantitative diffusion tensor imaging detects dopaminergic neuronal degeneration in a murine model of Parkinson's disease. Neurobiol Dis 2007;26:590-596.
28. Van Camp N, Blockx I, Verhoye M, et al. Diffusion tensor imaging in a rat model of Parkinson's disease after lesioning of the nigrostriatal tract. NMR Biomed 2009;22:697-706.
29. Kachergus J, Mata IF, Hulihan M, et al. Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. Am J Hum Genet 2005;76:672-680.
30. Hulihan MM, Ishihara-Paul L, Kachergus J, et al. LRRK2 Gly2019Ser penetrance in Arab-Berber patients from Tunisia: a case-control genetic study. Lancet Neurol 2008;7:591-594.
31. Latourelle JC, Sun M, Lew MF, et al. The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson's disease: the GenePD study [serial online]. BMC Med 2008;6:32.
32. Healy DG, Falchi M, O'Sullivan SS, et al.; International LRRK2 Consortium. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol 2008;7:583-590.
33. Stoessl AJ, Martin WW, McKeown MJ, Sossi V. Advances in imaging in Parkinson's disease. Lancet Neurol 2011;10:987-1001.